RCUS logo

RCUS Arcus Biosciences Inc

$24.44
$0.79
(3.13%)
Today
Closed $24.44
$0.10
(0.41%)
After Hours
46

Neutral Sentiment

How do you feel about RCUS?

Loading...
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Companys Board of Directors...
Business Wire
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast...
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Companys Board of...
Business Wire
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming...
Business Wire
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm PR Newswire NEW YORK, Aug. 19, 2026 NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...
PR Newswire
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Companys Board of...
Business Wire
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +26.53% and +186.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the second quarter ended June 30...
Business Wire